Molecular Mechanisms of Preeclampsia: 
Implications for Cardiovascular Disease and Chronic Kidney Disease

S. Ananth Karumanchi, M.B.B.S.
Medallion Chair in Vascular Biology
Director, Renovascular Research Center
Professor of Medicine
Cedars-Sinai Medical Center

Course Directors: Thomas J. Wang, M.D. and Salahuddin Kazi, M.D.

Purpose and Content
This program is designed to:
1. Provide an ongoing forum to obtain information about new developments in Internal Medicine utilizing lectures, slides, and a detailed protocol including illustrations and extensive bibliography, and a Q&A format.
2. Facilitate interactions between various subspecialties of Internal Medicine and broaden understanding of changes in practice patterns in other subspecialties.

Target Audience
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Educational Objectives
At the conclusion of this activity, the participant should be able to:
1. Discuss recent clinical and research advances in the various subspecialties of Internal Medicine.
2. Describe and identify current treatment approaches.
3. Develop comprehensive plans for care of complex patients.

Educational Method
Lecture, slides, protocol and a Q&A format.

Accreditation: The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Texas Southwestern Medical Center designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accrediting Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company (any entity whose primary business is producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).